
Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B 4-dose regimen for hemodialysis patients, determining the path forward toward approval.
Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B 4-dose regimen for hemodialysis patients, determining the path forward toward approval.
Study examines the scarcity of data on the incidence of HBV-related hepatocellular carcinoma in West Africa.
On the day of a FDA PDUFA for a hepatitis B vaccine, it serves as reminder of great progress, but there remains a need to proliferate education especially around the liver.
From July to November 2021, cruise ships accommodating COVID-19-vaccinated individuals implemented almost identical nonpharmaceutical protocols.
In the second installment of the discussion around the Equity in Antimicrobial Stewardship Efforts (EASE), the codevelopers of this novel framework discuss how to move forward with interventions and measuring success around them.
During July–September 2023 the role of irrigation water in City A's E coli outbreak.
Antimicrobial stewardship to reduce multidrug resistance and opportunistic Clostridioides difficile infection (CDI) could also guide shorter treatment.
A comparative study presented MAD-ID, The Antimicrobial Stewardship Meeting examining the effectiveness of ceftaroline and vancomycin in addressing this challenge.
A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.
The new Equity in Antimicrobial Stewardship Efforts (EASE) is a comprehensive set of priorities designed to overcome inequities and address the challenges with prescribing practices within the minoritized populations.
This week, new WHO data illustrates challenges during the acute phase of the COVID-19 pandemic, MAD-ID and ACVR conference coverage, and more from Contagion.
The federal agency said that due to administrative constraints, they will not complete the review of mRNA-1345 by the PDUFA date of May 12.
This study, presented at MAD-ID, The Antimicrobial Stewardship Meeting, evaluates patients with mild COVID-19 symptoms compared to those with severe cases.
Trial analyses presented at MAD-ID, The Antimicrobial Stewardship Meeting, highlight the battle against recurrent health care-associated infections (HAI).
The PERSEUS study aimed to assess the effectiveness and safety of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin presented at the 34th ESCMID Global conference.
Insights from the Annual Conference on Vaccinology Research (ACVR) in mitigating severe outcomes in older adults and individuals with underlying medical conditions.
Stating low demand, the company is removing their ChAdOx1-S [recombinant] (Vaxzevria) vaccine from the market.
Insights from the Annual Conference on Vaccinology Research (ACVR) on vaccine registries and assessing the safety of maternal and fetal health.
The investigational vaccine, mRNA-1345, developed for seniors has its FDA PDUFA date in a few days.
Investigating the long-term efficacy beyond short-term benefits.
In patients with Clostridium difficile infection (CDI), ibezapolstat was shown to have similar results to a standard of care therapy.
Despite overall reductions, the elderly remain vulnerable to severe COVID-19 outcomes.
New data from a World Health Organization (WHO) repository illustrates the treatment challenges during the acute phase of the pandemic.
The accuracy of ICD-10 varied depending on the patient's age, how the influenza season was defined, the time interval between symptom onset and testing, and the clinical setting.
Spare use of carbapenem-sparing regimens reflects practice lagging behind guidance, among the challenges in implementing antimicrobial stewardship.
The Department of Agriculture has initiated proactive measures, collaborating with federal agencies, to ensure the safety of the nation's meat supply.
According to the latest Centers for Disease Control and Prevention (CDC) data, these strains have increased in incidence rates, and now account for nearly a third of all US cases.
Analysis reveals rising hospitalization rates among pregnant women with hepatitis C virus (HCV) and age as a critical factor influencing maternal and fetal health outcomes.
The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.
This week, April FDA roundup, ESCMID conference coverage, enhancing C difficile treatment, and more from Contagion.